TriSalus Life Sciences Inc. Total Assets
TriSalus Life Sciences Inc. total assets. Based on the latest financial reports, TriSalus Life Sciences Inc. (TLSI) holds total assets worth $62.45 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of TriSalus Life Sciences Inc. for the company's overall valuation and market capitalisation.
Total Assets of TriSalus Life Sciences Inc. (2021–2025)
Total assets of TriSalus Life Sciences Inc. from 2021 to 2025. This chart illustrates how TriSalus Life Sciences Inc.'s total assets have evolved over time, based on quarterly financial data. See TriSalus Life Sciences Inc. share price for real-time trading data and today's change.
TriSalus Life Sciences Inc. - Asset Composition Analysis
TriSalus Life Sciences Inc. Total Assets Breakdown (December 2025)
TriSalus Life Sciences Inc. total assets breakdown as of December 2025. TriSalus Life Sciences Inc.'s total assets of $62.45 Million consist of 91.3% current assets and 8.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 57.9% |
| Accounts Receivable | $6.56 Million | 18.6% |
| Inventory | $3.08 Million | 8.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how TriSalus Life Sciences Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TLSI working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TriSalus Life Sciences Inc.'s current assets represent 91.3% of total assets in 2025, a decrease from 92.9% in 2021.
- Cash Position: Cash and equivalents constituted 57.9% of total assets in 2025, down from 80.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 18.6% of total assets.
TriSalus Life Sciences Inc. Competitors by Total Assets
Key competitors of TriSalus Life Sciences Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Demant A/S
CO:DEMANT
|
Denmark | Dkr39.07 Billion |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
China | CN¥2.34 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
PULSION Medical Systems SE
MU:PUS
|
Germany | €35.15 Million |
|
Cleo Diagnostics Ltd
AU:COV
|
Australia | AU$9.96 Million |
|
Memphasys Ltd
AU:MEM
|
Australia | AU$10.45 Million |
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
Australia | AU$139.55 Million |
TriSalus Life Sciences Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.35 | 4.08 | 1.01 |
| Quick Ratio | 4.97 | 3.68 | 0.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $48.57 Million | $28.76 Million | $5.81K |
TriSalus Life Sciences Inc. - Advanced Valuation Insights
This section examines the relationship between TriSalus Life Sciences Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 52.64 |
| Latest Market Cap to Assets Ratio | 5.66 |
| Asset Growth Rate (YoY) | 47.4% |
| Total Assets | $35.33 Million |
| Market Capitalization | $200.12 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values TriSalus Life Sciences Inc.'s assets at a significant premium (5.66x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: TriSalus Life Sciences Inc.'s assets grew by 47.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TriSalus Life Sciences Inc. (2021–2025)
The table below shows the annual total assets of TriSalus Life Sciences Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $35.33 Million | +47.39% |
| 2024-12-31 | $23.97 Million | -2.55% |
| 2023-12-31 | $24.60 Million | +11.83% |
| 2022-12-31 | $22.00 Million | -41.87% |
| 2021-12-31 | $37.84 Million | -- |
About TriSalus Life Sciences Inc.
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial… Read more